Expert Interview
A second look: Discussing Regeneron's Eylea (aflibercept) HD uptake and trends following the April 1 J-Code
Ticker(s): REGN, RHHBYInstitution: Duke
- Vitreoretinal Surgeon, Professor of Ophthalmology & Associate Professor of Surgery at Duke University School of Medicine, Associate Chief of Staff, Durham VA Health System and Co-Director of Duke Neurodegenerative Disease Retinal Imaging Repository.
- Manages 200 patients/month with Macular Edema & 250 patients (total) with Geographic Atrophy.
- Co-authored over 150 publications in peer-reviewed medical journals and over 50 textbook chapters; Leads an international multidisciplinary clinical research team evaluating multimodal retinal and optic nerve imaging for the diagnosis of Alzheimer's disease and other neurodegenerations.
Roughly how many patients do you manage with wet amd?
Added By: wilson_adminHow many are on Eylea?
Added By: wilson_adminHow will the J code impact your prescribing patterns?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
